RecruitingNCT07367282
Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration
PHASE4 · 64 planned enrolment
- Countries listed
- 1
- Registry update
- July 27, 2026
immortal.lifeTrial registrations containing the exact intervention label Faricimab Injection [Vabysmo].
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE4 · 64 planned enrolment
Phase not reported · 742 planned enrolment